Mersana Therapeutics Surges 69% After Reporting Positive Interim Data from the Expansion Portion of the XMT-1536 Phase 1 Study

Achieved 35% objective response rate, including 10% complete response rate, and 80% disease control rate among twenty evaluable patients with ovarian cancer Data continue to …